1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Elara Pharmaceuticals GmbH - Product Pipeline Review - 2013

Elara Pharmaceuticals GmbH - Product Pipeline Review - 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 22 pages

Elara Pharmaceuticals GmbH - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Elara Pharmaceuticals GmbH - Product Pipeline Review - 2013” provides data on the Elara Pharmaceuticals GmbH’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Elara Pharmaceuticals GmbH’s corporate website, SEC filings, investor presentations and featured press releases, both from Elara Pharmaceuticals GmbH and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Elara Pharmaceuticals GmbH - Brief Elara Pharmaceuticals GmbH overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Elara Pharmaceuticals GmbH human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Elara Pharmaceuticals GmbH with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Elara Pharmaceuticals GmbH’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Elara Pharmaceuticals GmbH’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Elara Pharmaceuticals GmbH in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Elara Pharmaceuticals GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Elara Pharmaceuticals GmbH.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Elara Pharmaceuticals GmbH and identify potential opportunities in those areas.

Table Of Contents

Elara Pharmaceuticals GmbH - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Elara Pharmaceuticals GmbH Snapshot 4
Elara Pharmaceuticals GmbH Overview 4
Key Information 4
Key Facts 4
Elara Pharmaceuticals GmbH - Research and Development Overview 5
Key Therapeutic Areas 5
Elara Pharmaceuticals GmbH - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Elara Pharmaceuticals GmbH - Pipeline Products Glance 9
Elara Pharmaceuticals GmbH - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Discovery Products/Combination Treatment Modalities 10
Elara Pharmaceuticals GmbH - Drug Profiles 11
BAZ Series 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
EL-101 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
EL-102 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
EL-103 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
THQ Series 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Elara Pharmaceuticals GmbH - Pipeline Analysis 16
Elara Pharmaceuticals GmbH - Pipeline Products by Therapeutic Class 16
Elara Pharmaceuticals GmbH - Pipeline Products By Target 17
Elara Pharmaceuticals GmbH - Pipeline Products by Route of Administration 18
Elara Pharmaceuticals GmbH - Pipeline Products By Mechanism of Action 19
Elara Pharmaceuticals GmbH - Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 22
Disclaimer 22



List of Tables

Elara Pharmaceuticals GmbH, Key Information 4
Elara Pharmaceuticals GmbH, Key Facts 4
Elara Pharmaceuticals GmbH - Pipeline by Indication, 2013 6
Elara Pharmaceuticals GmbH - Pipeline by Stage of Development, 2013 7
Elara Pharmaceuticals GmbH - Monotherapy Products in Pipeline, 2013 8
Elara Pharmaceuticals GmbH - Preclinical, 2013 9
Elara Pharmaceuticals GmbH - Discovery, 2013 10
Elara Pharmaceuticals GmbH - Pipeline By Therapeutic Class, 2013 16
Elara Pharmaceuticals GmbH - Pipeline By Target, 2013 17
Elara Pharmaceuticals GmbH - Pipeline By Route of Administration, 2013 18
Elara Pharmaceuticals GmbH - Pipeline Products By Mechanism of Action, 2013 19



List of Figures

Elara Pharmaceuticals GmbH - Pipeline by Indication, 2013 6
Elara Pharmaceuticals GmbH - Pipeline by Stage of Development, 2013 7
Elara Pharmaceuticals GmbH - Monotherapy Products in Pipeline, 2013 8
Elara Pharmaceuticals GmbH - Pipeline Products By Mechanism of Action, 2013 19



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.